DOCSLIB.ORG

Cambridgeshire Joint Prescribing Group 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cambridgeshire Joint Prescribing Group 2004 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG CAMBRIDGESHIRE & PETERBOROUGH CCG FORMULARY Classification of Prescribing Responsibility Skip to Alphabetical Index Foreword This document is an appendix to the Cambridgeshire and Peterborough CCG Formulary Medicines considered by the CPJPG are included in this document. In general, only medicines classified as ‘NOT RECOMMENDED’ and ‘HOSPITAL ONLY’ are retained in this document long-term whilst all others are removed after 6 months as they are included in the CCG Formulary. Definitions of the recommendations made by the Cambridgeshire and Peterborough Joint Prescribing Group (CPJPG) can be found in the explanatory notes Any medication/drug licensed or becoming available after the revision date (below) for this document and not considered by CPJPG should be regarded as ‘Not Recommended’ or ‘Hospital only’. Omission of a drug from this table cannot be taken to indicate that it is recommended for prescribing in either primary or secondary care. (i.e. any medicine not listed in either the classification table or the formulary are classified as “Not recommended” ) Please contact the Medicines Management Team for further advice. Cambridgeshire and Peterborough CCG have undertaken a prioritisation process and agreed that some therapies will not be a priority for funding and will therefore not be funded other than in exceptional circumstances. This appendix to the formulary is a continually evolving document and will be updated after each CPJPG meeting (every 2 months). We want it to be as useful as possible for our clinicians therefore the Medicines Management Team would welcome any feedback. Where commissioning responsibility for medication is now NHS England’s, the date last reviewed by CPJPG has been amended to Apr 2013*. REVISION DATE: 18th March 2016 (More detailed information about amendments made can be found here) Page 1 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG Alphabetical Index Letters below are hyperlinked – click on the letter that corresponds to the first letter of the generic drug name, e.g. ‘p’ for paracetamol. A N B O C P D Q E R F S G T H U I V J W K X L Y M Z Page 2 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG A Prior Approval Document Abatacept Rheumatoid Decision HOSPITAL ONLY March 2016 TA375 (Orencia) Arthritis √ remains active CCG Rheumatoid Arthritis Pathway Prior Approval Document(Adults Abatacept Juvenile idiopathic √ √ Decision HOSPITAL ONLY only) Nov 2016 TA373 (Orencia) arthritis (paeds) (adults) remains active Paediatrics - NHSE Abiraterone Prostate cancer HOSPITAL ONLY √ N/A Apr 2013* N/A N/A PrescQIPP Medical Accel-heal Devices Drop list (Electrical Wound NOT Decision √ Guidance March 2017 N/A stimulating wound management RECOMMENDED remains active (login may be device) required) Safety concerns, strict Psoriasis, Acitretin NOT monitoring Decision Ichthyosis, Darier’s √ N/A (Neotigason) RECOMMENDED requirements and remains active disease restricted availability. HOSPITAL ONLY Adjunctive therapy Acetylcysteine to immuno- Medication supplied CPJPG Decision or suppressants in direct from √ May 2010 N/A CG163 Summary N-acetylcysteine idiopathic Papworth Hospital pulmonary fibrosis for patients under their care Page 3 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG CPJPG Decision Aclidinium + Summary Decision formoterol COPD RECOMMENDED √ July 2015 CG101 remain active (Duaklir Genuair) See COPD Pathway Ankylosing Adalimumab spondylitis & non- Prior Approval Decision HOSPITAL ONLY √ TA383 (Humira) radiographic axial Document remains active spondyloarthritis Adalimumab Crohn’s (Adult Prior Approval Decision HOSPITAL ONLY √ Nov 2010 TA187 (Humira) patients) Document remains active Adalimumab Crohn’s (Paediatric Decision HOSPITAL ONLY √ N/A Apr 2013* N/A (Humira) patients) remains active Historical Adalimumab Prior Approval Decision Psoriasis HOSPITAL ONLY √ decision TA146 (Humira) Document remains active Adalimumab Prior Approval Decision Psoriatic arthritis HOSPITAL ONLY √ Jul 2006 TA199 (Humira) Document remains active Adalimumab Rheumatoid HOSPITAL ONLY Prior Approval Decision √ March 2016 TA375 (Humira) arthritis Document remains active Prior Approval Document(Adults Adalimumab Juvenile idiopathic √ √ Decision HOSPITAL ONLY only) Nov 2016 TA373 (Humira) arthritis (paeds) (adults) remains active Paediatrics - NHSE Ulcerative colitis Adalimumab Prior Approval Decision (moderate to HOSPITAL ONLY √ March 2015 TA329 (Humira) Document remains active severe) Page 4 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG √ Adalimumab Non-infectious Decision HOSPITAL ONLY (Tertiary N/A Sept 2017 TA460 (Humira) uveitis remains active centre) Non-small cell lung Afatinib HOSPITAL ONLY √ N/A Apr 2013* N/A N/A cancer Wet age-related Aflibercept Prior Approval Decision macular HOSPITAL ONLY √ Mar 2014 TA294 (Eylea) Document remains active degeneration Visual impairment caused by macular Aflibercept oedema secondary Prior Approval Jul 2014 Decision TA305 HOSPITAL ONLY √ (Eylea) to central or branch Document Nov 2016 remains active TA409 retinal vein occlusion Aflibercept Diabetic Macular Prior Approval Decision HOSPITAL ONLY √ Sep 2015 TA346 (Eylea) Oedema Document remains active Agalsidase beta (Fabrazyme, Fabrys disease HOSPITAL ONLY √ N/A Apr 2013* N/A N/A Replagal) Evidence for suggested place in therapy was insufficient to gain acceptance. Agomelatine NOT Decision Severe Depression √ Nov 2009 N/A (Valdoxan) RECOMMENDED remains active There is currently no view on use of the drug from the Mental Health Trust. The drug would not meet Page 5 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG the NICE criteria for cost-effectiveness. PrescQIPP Medical Devices Drop list Aknicare NOT Decision Acne √ Guidance March 2017 N/A (all formulations) RECOMMENDED remains active (login may be required) RECOMMENDED with SHARED CARE Alemtuzumab Relapsing remitting Decision √ Shared care Jan 2015 TA312 (Lemtrada) Multiple Sclerosis (Medication not for remains active prescribing in primary care. This is supplied by CUHFT) Generic prescribing of alendronic acid is Alendronic acid/ advised with separate NOT Nov 2009 Decision colecalciferol Osteoporosis √ calcium and vitamin D TA161 RECOMMENDED remains active (Fosavance) supplementation. Alirocumab Hypercholesterolae Prior Approval Decision HOSPITAL ONLY √ July 2016 TA 393 (Praluent) mia Document remains active Page 6 of 97 Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG Steroid Refractory Decision Alitretinoin Prior Approval Severe Chronic HOSPITAL ONLY √ May 2011 remains active TA177 (Toctino) Document Hand Eczema Alprostadil 3mg/g Erectile dysfunction NOT CPJPG Decision Decision √ Jul 2014 N/A cream (Vitaros) RECOMMENDED Summary remains active Acute ischaemic Historical Decision TA52 HOSPITAL ONLY √ N/A Alteplase stroke decision remains active TA122 Ambrisentan Class III Pulmonary (Volibris) Arterial HOSPITAL ONLY √ N/A Jan 2009 N/A N/A Hypertension Amifampridine Lambert-Eaton phosphate myasthenic HOSPITAL ONLY √ N/A Apr 2013* N/A N/A (Firdapse) syndrome (LEMS) non-CF Decision HOSPITAL ONLY √ N/A March 2017 N/A bronchiectasis remains active Amikacin (via Homecare) Amlodipine Non-formulary. Historical besylate/ NOT Decision Hypertension √ Generic prescribing decision N/A valsartan RECOMMENDED remains active recommended. (Exforge) Contains a non- Amlodipine/ formulary angiotensin Historical olmesartan Essential NOT Decision √ II receptor antagonist. decision N/A (Sevikar) Hypertension RECOMMENDED remains active Inflexible dosage form. Amorolfine % nail Fungal nail See Anti-fungal nail lacquers lacquer infection Licensed for 2nd line use following lack of Anagrelide Essential thrombo- Decision HOSPITAL ONLY √ effectiveness or May
Load more

Recommended publications
  • NEW Products
    NEW Products NEW Products - January 2021 NEW Generics PIP CODE PRODUCT PACK 1236082 Dexamethasone Tablets 500mcg 28 7747462 Diltiazem Tablets 60mg 84 5018957 Mebeverine 50mg/5ml Oral Suspension 300ml NEW UK Feeds PIP CODE PRODUCT PACK 3655545 Fresubin 2kcal Fibre Apricot/Peach 4x200m 3 NEW Products 3442803 Fresubin 2kcal Fibre Cappucino 4x200m 3438264 Fresubin 2kcal Fibre Chocolate 4x200m 3442795 Fresubin 2kcal Fibre Lemon 4x200m 5 Generics 3655537 Fresubin 2kcal Fibre Neutral 4x200m www.de-group.co.uk 3442944 Fresubin 2kcal Fibre Vanilla Pack 4x200m 4022950 Fresubin 2kcal Mini Apricot/Peach 4x125m 44 Parallel Imports 4022976 Fresubin 2kcal Mini Fibre Chocolate 4x125m 4022984 Fresubin 2kcal Mini Fibre Vanilla 4x125m 4022968 Fresubin 2kcal Mini FOTF 4x125m 3 60 UK Ethicals 4022943 Fresubin 2kcal Mini Vanilla 4x125m 3771334 Polycal Liquid Bottle Neutral 200ml 3771326 Polycal Liquid Bottle Orange 200ml 70 UK Feeds NEW UK Dressings PIP CODE PRODUCT PACK 74 Parallel Import Feeds 3272887 Airzone Peak Flow Meter 15 3793965 Biatain Adhesive 7.5x7.5 10 3798469 Clinifilm Wipes 30 76 Dressings 3902756 Clinimed LBF Foam Applicator 2ml 5 2896439 Clinimed LBF NonSting Bar Film Wipes 30 90 3694924 Cutimed Protect Cream 90g OTC 3694916 Cutimed Protect Cream 28g 3694890 Cutimed Protect Foam 1ml 5 3694908 Cutimed Protect Foam 3ml 5 134 Dispensing 3694882 Cutimed Protect Spray 28ml 3722238 Cutimed Sorbion Sachet Extra 20x10 5 3883402 Cutimed Sorbion Sachet XL 45cmx25cm 5 136 Vets 3942018 Devon Foot And Heel Protector 2 227074 Kaltostat Rope Cavity Wound
    [Show full text]
  • Laws of Trinidad and Tobago Ministry of Legal Affairs
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 3–20 .. 21–245 .. UNOFFICIAL VERSION L.R.O. UPDATED TO DECEMBER 31ST 2014 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Food and Drugs Act 2005
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 1/2009 3–20 .. 1/2006 21–245 .. 1/2009 L.R.O. 1/2009 UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Bk Sans 005737.Pdf
    TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington
    [Show full text]
  • Additions to the Automation List from 1St January 2012
    Additions to the Automation List from 1st January 2012 Acular Drops .5 % Packsize 5 Broflex Syrup 5 Mg/5ml Packsize 200 Alfacalcidol Drops 2 Mcg/Ml Packsize 10 Brolene Drops .1 % Packsize 10 Alimemazine Tartrate Syrup 30 Mg/5ml Packsize 100 Budelin Novolizer Inhal 200 Mcg/Dose Packsize 1 Alomide Drops .1 % Packsize 5 Budelin Novolizer Inhal 200 Mcg/Dose Packsize 1 Alpha Tocopheryl Acetate Susp 500 Mg/5ml Budesonide Inhal 200 Mcg/Dose Packsize 1 Packsize 100 Budesonide Inhal 200 Mcg/Dose Packsize 1 Altacite Plus Susp Packsize 100 Budesonide Inhal 400 Mcg/Dose Packsize 1 Altacite Plus Susp Packsize 500 Budesonide Spray 64 Mcg/Dose Packsize 1 Alvesco Inhal 160 Mcg/Dose Packsize 1 Bumetanide Liq 1 Mg/5ml Packsize 150 Alvesco Inhal 160 Mcg/Dose Packsize 1 Buserelin Spray 150 Micrograms Packsize 2 Alvesco Inhal 80 Mcg/Dose Packsize 1 Calcitonin (Salmon) Spray 200 Units/Dose Packsize Amantadine Hydrochloride Syrup 50 Mg/5ml 1 Packsize 150 Calpol Infant Susp 120 Mg/5ml Packsize 100 Amoxicillin Syrup 125 Mg/5ml Packsize 100 Calpol Six Plus Susp 250 Mg/5ml Packsize 100 Amoxicillin Syrup 250 Mg/5ml Packsize 100 Calpol Six Plus Susp 250 Mg/5ml Packsize 200 Ampicillin Susp 125 Mg/5ml Packsize 100 Calprofen Susp 100 Mg/5ml Packsize 100 Anbesol Liq Packsize 15 Canesten Af Spray 1 % Packsize 1 Anbesol Liq Packsize 6.5 Canesten Spray 1 % Packsize 1 Antepsin Susp 1 G/5ml Packsize 250 Carbocisteine Syrup 125 Mg/5ml Packsize 300 Apraclonidine Drops .5 % Packsize 5 Carmellose Sodium Drops .5 % Packsize 30 Apraclonidine Drops 1 % Packsize 24 Carmellose Sodium
    [Show full text]
  • Journal Officiel De L'union Européenne 23.9.2003
    450 FR Journal officiel de l'Union européenne 23.9.2003 Appendice A visé au Chapitre 1, point 2, de l'annexe XI (*) Liste, fournie en une seule langue par Malte, des médicaments pour lesquels l'autorisation de mise sur le marché délivrée en vertu du droit maltais avant la date d'adhésion demeurera valable jusqu'à ce qu'elle soit renouvelée conformément à l'acquis ou jusqu'au 31 décembre 2006, si cette dernière date est plus proche. L'inscription d'un médicament sur cette liste ne signifie pas forcément que l'autorisation de mise sur le marché obtenue est conforme à l'acquis. LISTE DES MÉDICAMENTS À INCLURE DANS L'ARRANGEMENT NÉGOCIÉ DANS LE CADRE DU CHAPITRE I Trade Name Dosage Form Dose MA Holder Country 0.45% SODIUM CHLORIDE IN 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE AG 0.45% SODIUM CHLORIDE SOLUTION FOR 0.45% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.45% SODIUM CHLORIDE SOLUTION FOR IV 4.5MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION, USP INJECTION AMERICA 0.9% SOD. CHLORIDE AND 5% SOLUTION FOR N/A BAXTER HEALTHCARE UNITED KINGDOM GLUCOSE INJECTION LIMITED 0.9% SODIUM CHLORIDE AND 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE IV INF AG 0.9% SODIUM CHLORIDE SOLUTION FOR INJ 9MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 9MG/ML ABBOTT LABORATORIES UNITED STATES OF IRRIGATION IRRIGATION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF IRRIGATION USP IRRIGATION AMERICA 0.9% W/V SODIUM CHLORIDE SOLUTION FOR 0.9% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 0.9% W/V SODIUM CHLORIDE IRRIGATION SOLUTION 0.9% W/V B.BRAUN MELSUNGEN GERMANY IRRIGATION SOL.
    [Show full text]
  • Dokumenti” ES 13
    “Latvijas Vēstnesis. Dokumenti” ES 13. burtnīca Eiropas Savienības dokumenti LATVIJAS REPUBLIKASLALA OFICIÅLAISTVIJAS TVIJASLAIKRAKSTS V‰STNESISV‰STNESIS VALSTS NORMATÈVIE TIESÈBU AKTI Galvenais redaktorsLA — OSKARS GERTVIJASTS V‰STNESIS DOKUMENTI 2004.gads, 10.februåris EIROPAS SAVIENÈBAS DOKUMENTI EIROPAS SAVIENĪBAS DOKUMENTI Oficiålå publikåcija ES 13. burtnîca TRATADO RELATIVO A LA ADHESIÓN A LA UNIÓN EUROPEA 2003 SMLOUVA O PŘISTOUPENÍ K EVROPSKÉ UNII 2003 TRAKTAT OM TILTRÆDELSE AF DEN EUROPÆISKE UNION 2003 VERTRAG ÜBER DEN BEITRITT ZUR EUROPÄISCHEN UNION 2003 2003. AASTA EUROOPA LIIDUGA ÜHINEMISE LEPING ΣΥΝΘΗΚΗ ΠΡΟΣΧΩΡΗΣΕΩΣ ΣΤΗΝ ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ 2003 TREATY OF ACCESSION TO THE EUROPEAN UNION 2003 TRAITE RELATIF A L’ADHESION A L’UNION EUROPEENNE DE 2003 CONRADH AONTACHAIS LEIS AN AONTAS EORPACH 2003 TRATTATO DI ADESIONE ALL’UNIONE EUROPEA 2003 LĪGUMS PAR PIEVIENOŠANOS EIROPAS SAVIENĪBAI, 2003 2003 M. STOJIMO Į EUROPOS SĄJUNGĄ SUTARTIS AZ EURÓPAI UNIÓHOZ TÖRTÉNŐ CSATLAKOZÁSRÓL SZÓLÓ SZERZŐDÉS 2003 IT-TRATTAT TA’ L-ADEŻJONI MA’ L-UNJONI EWROPEA 2003 VERDRAG BETREFFENDE DE TOETREDING TOT DE EUROPESE UNIE 2003 TRAKTAT O PRZYSTĄPIENIU DO UNII EUROPEJSKIEJ 2003 TRATADO DE ADESÃO À UNIÃO EUROPEIA DE 2003 ZMLUVA O PRISTÚPENÍ K EURÓPSKEJ ÚNII 2003 POGODBA O PRISTOPU K EVROPSKI UNIJI 2003 SOPIMUS LIITTYMISESTÄ EUROOPAN UNIONIIN 2003 FÖRDRAGET OM ANSLUTNING TILL EUROPEISKA UNIONEN 2003 Akts par pievienošanās nosacījumiem un pielāgojumiem līgumos, kas ir Eiropas Savienības pamatā X I p i e l i k u m s. Pievienošanās akta 24. pantā minētais saraksts: Malta P i e l i k u m a Farmaceitisko produktu saraksts, kas iekļaujams pie pasākumiem, A p a p i l d i n ā j u m s.
    [Show full text]
  • Introduction to Renal Therapeutics
    Introduction to Renal Therapeutics Introduction to Renal Therapeutics Edited by Caroline Ashley MSc, BPharm (Hons), MRPharmS Lead Specialist Pharmacist, Renal Services Royal Free Hospital Royal Free Hampstead NHS Trust London, UK Clare Morlidge BPharm (Hons), DipClinPharm, MRPharmS Cardiothoracic Directorate Pharmacist Lister Hospital East and North Hertfordshire NHS Trust Hertfordshire, UK On behalf of the UK Renal Pharmacy Group London • Chicago Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SE1 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030–7820, USA © Pharmaceutical Press 2008 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First published 2008 Typeset by Photoprint, Torquay, Devon Printed in Great Britain by Cambridge University Press, Cambridge ISBN 978 0 85369 688 9 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of Caroline Ashley and Clare Morlidge to be identified as the authors of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. A catalogue
    [Show full text]
  • Full Automation List
    Automation List from 1st March 2012 Abidec Drops Packsize 25 Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Abilify Tabs 10 Mg Packsize 28 Pen Packsize 2 Abstral Tabs 100 Micrograms Packsize 10 Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Abstral Tabs 100 Micrograms Packsize 30 Syringe Packsize 2 Abstral Tabs 200 Micrograms Packsize 10 Adapalene Cream .1 % Packsize 45 Abstral Tabs 200 Micrograms Packsize 30 Adapalene Gel .1 % Packsize 45 Abstral Tabs 300 Micrograms Packsize 10 Adartrel Tabs 2 Mg Packsize 28 Abstral Tabs 300 Micrograms Packsize 30 Adartrel Tabs 250 Micrograms Packsize 12 Abstral Tabs 400 Micrograms Packsize 10 Adartrel Tabs 500 Micrograms Packsize 28 Abstral Tabs 400 Micrograms Packsize 30 Adcal 1.5 G Sf Contains Calcium 600mg Chewable Tabs Abstral Tabs 600 Micrograms Packsize 30 Packsize 100 Acamprosate Calcium 333 Mg Ec Tabs Packsize 168 Adcal D3 Chewable Tabs Packsize 112 Acarbose Tabs 100 Mg Packsize 90 Adcal D3 Chewable Tabs Packsize 112 Acarbose Tabs 50 Mg Packsize 90 Adcal D3 Chewable Tabs Packsize 56 Accolate Tabs 20 Mg Packsize 56 Adcal D3 Chewable Tabs Packsize 56 Accupro Tabs 10 Mg Packsize 28 Adcal D3 Dissolve Effervescent Tabs Packsize 56 Accupro Tabs 20 Mg Packsize 28 Adcal D3 Tabs Packsize 112 Accupro Tabs 40 Mg Packsize 28 Adefovir Dipivoxil Tabs 10 Mg Packsize 30 Accupro Tabs 5 Mg Packsize 28 Adenuric Tabs 80 Mg Packsize 28 Accuretic Tabs Packsize 28 Adipine 10 Mr 10 Mg Tabs Packsize 56 Acebutolol Caps 100 Mg Packsize 84 Adipine 20 Mr 20 Mg Tabs Packsize 56 Acebutolol
    [Show full text]
  • 450 Official Journal of the European Union 23.9.2003
    450EN Official Journal of the European Union 23.9.2003 Appendix A referred to in Chapter 1, point 2 of Annex XI (*) Lists as provided by Malta in one language of pharmaceutical products for which a marketing authorisation issued under Maltese law prior to the date of accession shall remain valid until it is renewed in compliance with the acquis or until 31 December 2006, whichever is the earlier. Mention on this list does not prejudge whether or not the pharmaceutical product in question has a marketing authorisation in compliance with the acquis. LIST OF PHARMACEUTICALS TO BE INCLUDED UNDER THE ARRANGEMENT NEGOTIATED UNDER CHAPTER 1 Trade Name Dosage Form Dose MA Holder Country 0.45% SODIUM CHLORIDE IN 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE AG 0.45% SODIUM CHLORIDE SOLUTION FOR 0.45% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.45% SODIUM CHLORIDE SOLUTION FOR IV 4.5MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION, USP INJECTION AMERICA 0.9% SOD. CHLORIDE AND 5% SOLUTION FOR N/A BAXTER HEALTHCARE UNITED KINGDOM GLUCOSE INJECTION LIMITED 0.9% SODIUM CHLORIDE AND 5% INFUSION SOLUTION N/A B.BRAUN MELSUNGEN GERMANY GLUCOSE IV INF AG 0.9% SODIUM CHLORIDE SOLUTION FOR INJ 9MG/ML ABBOTT LABORATORIES UNITED STATES OF INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF INJECTION USP INJECTION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 9MG/ML ABBOTT LABORATORIES UNITED STATES OF IRRIGATION IRRIGATION AMERICA 0.9% SODIUM CHLORIDE SOLUTION FOR 0.9% ABBOTT LABORATORIES UNITED STATES OF IRRIGATION USP IRRIGATION AMERICA 0.9% W/V SODIUM CHLORIDE SOLUTION FOR 0.9% W/V B.BRAUN MELSUNGEN GERMANY INJECTION BP INJECTION AG 0.9% W/V SODIUM CHLORIDE IRRIGATION SOLUTION 0.9% W/V B.BRAUN MELSUNGEN GERMANY IRRIGATION SOL.
    [Show full text]
  • The South East London Red, Amber, Grey (RAG) Medicines List for Adults - Updated January 2020
    The South East London Red, Amber, Grey (RAG) medicines list for adults - updated January 2020 Definitions and notes to accompany the RAG list NON FORMULARY Drugs are included as a separate RAG list and shaded blue to guide prescribers regarding out of area requests. Requests for GPs to prescribe non-formulary drugs should be returned to the specialist and not prescribed in primary care. Inclusion of a drug on the RAG list does not confer that a drug is commissioned for use within SEL trusts, please refer to the SEL joint formulary. Definition of RED • A consultant or suitably trained specialist (e.g. a specialist non-medical prescribing nurse) within the secondary, tertiary, or primary care clinic should initiate, continue to prescribe and monitor red listed drugs. • RED list drugs are NOT recommended for GPs to prescribe and responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients. • Supply of these medicines should be organised through the hospital pharmacy or where appropriate a home care company. If it is necessary to supply on a FP10HNC (previously FP10HP), liaison with a nominated community pharmacy is recommended. • Medicines for specified indications included in the red list should only be prescribed subject to inclusion in the SEL Joint Medicines Formulary and funding being arranged at the individual acute Trust.
    [Show full text]
  • Menstrual Cups
    www.ethicalconsumer.org EC179 July/August 2019 £4.25 Pills & Profits Is choosing a painkiller still an ethical headache? Product guides to: Over-the-counter medicines Menstrual products Plus: Should we boycott Toilet paper Boots The Chemist? Nappies Editorial ethicalconsumer.org JULY/AUGUST 2019 Tim Hunt Editor As we went to print Donald Trump was in the UK, options for these products including reusable, organic telling us how well the US is doing on climate change and plastic free varieties. and making it clear that the NHS would have to be part Our third guide features an entirely disposable product, of any post Brexit trade deal (or maybe not). Whether toilet paper. Ubiquitous in the western world but less deliberately meant to confuse or the ramblings of a man so around the world this is a product that the phrase detached from reality, Trump’s befuddled messages ‘single-use’ was made for. Worryingly companies are circled round the edges of issues that UK citizens are using less recycled materials and more virgin forests beginning, in much greater numbers, to take seriously. than ever as people switch to luxury and quilted brands. Firstly climate change and the ecological crisis. Over Thankfully there are a number of ethical brands in the past couple of months we’ve seen significant street the market using 100% recycled materials. Meanwhile demonstrations, direct actions and school strikes, that some consumers are switching to less conventional have enjoyed popular support from across the political alternatives. spectrum and society in general. As a result councils have declared climate emergencies and political parties have promised change, albeit at a rate too slow for those Unpalatable medicines on the streets.
    [Show full text]